Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease?

(E-pub Ahead of Print)

Author(s): Kalle Landerholm, Disa Kalman, Conny Wallon, Pär Myrelid*.

Journal Name: Current Drug Targets

Become EABM
Become Reviewer


Crohn’s disease may severely impact quality of life and being a chronic disease it requires both medical and surgical treatment aimed at induction and maintenance of remission to prevent relapsing symptoms and the need of further surgery. Surgery in Crohn’s disease often has to be performed in patients with well-known risk factors of post-operative complications, particularly intra-abdominal septic complications. This review will look at the current knowledge of immunomodulating therapies in the peri-operative phase of Crohn’s disease. The influence of immunomodulators on post-operative complications is evaluated by reviewing available clinical reports and data from animal studies. Furthermore, the effect of immunomodulators on preventing or deferring primary as well as repeat surgery in Crohn’s disease is reviewed with particular consideration given to high-risk cohorts and timing of prophylaxis.

Keywords: Crohn’s disease, inflammatory bowel disease, surgery, immunomodulators, thiopurines, azathioprine, mercaptopurine.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450120666190617163919
Price: $95

Article Metrics

PDF: 3